Cargando…

Mitochondrial biomarkers predict tumor progression and poor overall survival in gastric cancers: Companion diagnostics for personalized medicine

Here, we employed a bioinformatics approach to identify novel molecular determinants to predict tumor progression and overall survival in gastric cancer patients. In particular, we directly assessed whether nuclear-derived mRNA species encoding proteins involved in mitochondrial protein translation...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sotgia, Federica, Lisanti, Michael P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620160/ https://www.ncbi.nlm.nih.gov/pubmed/28978020 http://dx.doi.org/10.18632/oncotarget.19962

Ejemplares similares

Mitochondrial mRNA transcripts predict overall survival, tumor recurrence and progression in serous ovarian cancer: Companion diagnostics for cancer therapy
por: Sotgia, Federica, et al.
Publicado: (2017)

Mitochondrial markers predict survival and progression in non-small cell lung cancer (NSCLC) patients: Use as companion diagnostics
por: Sotgia, Federica, et al.
Publicado: (2017)

Mitochondrial markers predict recurrence, metastasis and tamoxifen-resistance in breast cancer patients: Early detection of treatment failure with companion diagnostics
por: Sotgia, Federica, et al.
Publicado: (2017)

Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention?
por: Sotgia, Federica, et al.
Publicado: (2011)

Exploiting mitochondrial targeting signal(s), TPP and bis-TPP, for eradicating cancer stem cells (CSCs)
por: Ozsvari, Bela, et al.
Publicado: (2018)

High mitochondrial mass identifies a sub-population of stem-like cancer cells that are chemo-resistant
por: Farnie, Gillian, et al.
Publicado: (2015)

A new mutation-independent approach to cancer therapy: Inhibiting oncogenic RAS and MYC, by targeting mitochondrial biogenesis
por: Ozsvari, Bela, et al.
Publicado: (2017)

“Energetic” Cancer Stem Cells (e-CSCs): A New Hyper-Metabolic and Proliferative Tumor Cell Phenotype, Driven by Mitochondrial Energy
por: Fiorillo, Marco, et al.
Publicado: (2019)

Matcha green tea (MGT) inhibits the propagation of cancer stem cells (CSCs), by targeting mitochondrial metabolism, glycolysis and multiple cell signalling pathways
por: Bonuccelli, Gloria, et al.
Publicado: (2018)

Mitochondrial fission as a driver of stemness in tumor cells: mDIVI1 inhibits mitochondrial function, cell migration and cancer stem cell (CSC) signalling
por: Peiris-Pagès, Maria, et al.
Publicado: (2018)

High ATP Production Fuels Cancer Drug Resistance and Metastasis: Implications for Mitochondrial ATP Depletion Therapy
por: Fiorillo, Marco, et al.
Publicado: (2021)

Biomarker and Companion Diagnostics—A Review of Medicinal Products Approved by the European Medicines Agency
por: Orellana García, Laura Patricia, et al.
Publicado: (2021)

Mitochondrial and ribosomal biogenesis are new hallmarks of stemness, oncometabolism and biomass accumulation in cancer: Mito‐stemness and ribo‐stemness features
por: Peiris‐Pagès, Maria, et al.
Publicado: (2019)

Mitochondrial Fission Factor (MFF) Inhibits Mitochondrial Metabolism and Reduces Breast Cancer Stem Cell (CSC) Activity
por: Sánchez-Alvarez, Rosa, et al.
Publicado: (2020)

Deferiprone (DFP) Targets Cancer Stem Cell (CSC) Propagation by Inhibiting Mitochondrial Metabolism and Inducing ROS Production
por: Fiorillo, Marco, et al.
Publicado: (2020)

EuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine
por: van Dongen, J J M, et al.
Publicado: (2012)

Using the common cold virus as a naturally occurring vaccine to prevent COVID-19: Lessons from Edward Jenner
por: Sotgia, Federica, et al.
Publicado: (2020)

Mitochondrial “power” drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer
por: Fiorillo, Marco, et al.
Publicado: (2017)

Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics—Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer
por: Plönes, Till, et al.
Publicado: (2016)

The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy
por: Fiorillo, Marco, et al.
Publicado: (2018)

Mitoketoscins: Novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs)
por: Ozsvari, Bela, et al.
Publicado: (2017)

Proteomic identification of prognostic tumour biomarkers, using chemotherapy-induced cancer-associated fibroblasts
por: Peiris-Pagès, Maria, et al.
Publicado: (2015)

Bedaquiline, an FDA-approved drug, inhibits mitochondrial ATP production and metastasis in vivo, by targeting the gamma subunit (ATP5F1C) of the ATP synthase
por: Fiorillo, Marco, et al.
Publicado: (2021)

Increased MicroRNA-630 Expression in Gastric Cancer Is Associated with Poor Overall Survival
por: Chu, Dake, et al.
Publicado: (2014)

Aligning the Economic Value of Companion Diagnostics and Stratified Medicines
por: Blair, Edward D., et al.
Publicado: (2012)

A mitochondrial based oncology platform for targeting cancer stem cells (CSCs): MITO-ONC-RX
por: Sotgia, Federica, et al.
Publicado: (2018)

Hallmarks of the cancer cell of origin: Comparisons with “energetic” cancer stem cells (e-CSCs)
por: Sotgia, Federica, et al.
Publicado: (2019)

First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds
por: Ózsvári, Béla, et al.
Publicado: (2020)

COVID-19 and chronological aging: senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection?
por: Sargiacomo, Camillo, et al.
Publicado: (2020)

Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation
por: Bonuccelli, Gloria, et al.
Publicado: (2022)

Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy
por: Ozsvari, Bela, et al.
Publicado: (2017)

Mitochondrial biogenesis is required for the anchorage-independent survival and propagation of stem-like cancer cells
por: De Luca, Arianna, et al.
Publicado: (2015)

Cholesterol and Mevalonate: Two Metabolites Involved in Breast Cancer Progression and Drug Resistance through the ERRα Pathway
por: Brindisi, Matteo, et al.
Publicado: (2020)

Companion Diagnostics and Predictive Biomarkers for MET-Targeted Therapy in NSCLC
por: Jørgensen, Jan Trøst, et al.
Publicado: (2022)

Emerging biomedical imaging-based companion diagnostics for precision medicine
por: Liao, Shiyi, et al.
Publicado: (2023)

Chemotherapy induces the cancer-associated fibroblast phenotype, activating paracrine Hedgehog-GLI signalling in breast cancer cells
por: Peiris-Pagès, Maria, et al.
Publicado: (2015)

Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose
por: Peiris-Pagès, Maria, et al.
Publicado: (2015)

SOX2-high cancer cells exhibit an aggressive phenotype, with increases in stemness, proliferation and invasion, as well as higher metabolic activity and ATP production
por: Mauro-Lizcano, Marta, et al.
Publicado: (2022)

CGB5 expression is independently associated with poor overall survival and recurrence‐free survival in patients with advanced gastric cancer
por: Yang, Yuxin, et al.
Publicado: (2018)

COMPANION TO NEONATAL MEDICINE
Publicado: (1982)

Cannot write session to /tmp/vufind_sessions/sess_k89hpn10md3ngautmo4f2m263k